---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037962"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:00:45.254208+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q2 2023 revenue $108.3M (+21% YoY); reaffirms 2023 guidance

## Summary
- Q2 total revenue $108.3M vs $89.3M YoY; Crysvita $83.0M (+20%), Dojolvi $16.5M, Mepsevii $8.4M.
- Net loss $159.8M ($2.25/sh) compared to $158.2M ($2.26) in Q2 2022; cash and equivalents $618.4M.
- Reaffirmed FY2023 guidance: total revenue $425-450M, Crysvita $325-340M, Dojolvi $65-75M.
- Setrusumab Phase 2 OI data: 9.4% BMD increase at 20mg/kg in 3 months; Phase 3 Orbit/Cosmic enrolling.
- Howard Horn appointed CFO and EVP Corporate Strategy effective Oct 16, 2023.

## SEC filing metadata
- accession: 0000950170-23-037962
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017023037962/0000950170-23-037962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017023037962/rare-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037962
- JSON: https://secwatch.observer/filing/0000950170-23-037962.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037962.txt

## Key facts
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported the quarter ended June 30, 2023 results: revenue $108.3 million, net income net loss of $159.8 million, or $2.25 per share basic and diluted, EPS $2.25 per share basic and diluted. Guidance reaffirmed.
  - Period: the quarter ended June 30, 2023
  - Revenue: $108.3 million
  - Net income: net loss of $159.8 million, or $2.25 per share basic and diluted
  - EPS: $2.25 per share basic and diluted
  - Guidance: reaffirmed
  - Result: reported results
  source text: Mepsevii 8,439 4,933 16,919 9,794 Evkeeza 365 — 577 — Daiichi Sankyo — 1,479 1,479 4,728 Total revenues $ 108,309 $ 89,343 $ 208,805 $ 169,278 Total Revenues Ultragenyx reported $108.3 million in total revenue for the second quarter of 2023, which represents 21% growth compared to the second quarter 2022. This includes second quarter 2023 Crysvita revenue in North
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023037962/0000950170-23-037962-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.